Amyloid Plaque News and Research

RSS

Could the Mediterranean diet protect the brain through the gut?

A narrative review finds that the Mediterranean diet may support brain health through gut microbiome, immune, metabolic, and barrier-related pathways, but direct human evidence that microbiome remodeling mediates neuroprotection remains limited. The proposed mechanisms involve microbial metabolites, reduced inflammatory signaling, stronger intestinal and blood-brain barrier function, and possible effects on processes linked to Alzheimer’s and Parkinson’s diseases.

27 Sep 2026

New blood screening algorithm reduces unnecessary Alzheimer's PET scans

A new blood-based screening algorithm dramatically reduced the number of unnecessary PET scans needed to recruit patients at risk of Alzheimer's disease for a clinical trial, according to research from scientists at the Keck School of Medicine of USC published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

9 Sep 2026

Molecular switch ERBB4 linked to broad range of Alzheimer's pathologies

What if amyloid plaques are not the whole story of Alzheimer's disease? New research suggests that a broad range of Alzheimer's pathologies may be orchestrated by a molecular switch called ERBB4 when it turns on in the wrong neurons.

26 Aug 2026

Brain changes detect Alzheimer's seven years before plaques appear

A new study suggests that Alzheimer's disease may be detected by brain imaging more than seven years earlier than previously assumed. Researchers from the Department of Psychology at the University of Oslo led the study, published in Nature Neuroscience.

19 Aug 2026

Study advances understanding of mixed protein pathologies in dementia

The aging brain frequently harbors multiple protein pathologies that contribute to Alzheimer's, Parkinson's and other neurodegenerative diseases.

8 Jul 2026

Women with Parkinson's may be more vulnerable to Alzheimer's pathology

Women with Parkinson's disease may be more vulnerable to Alzheimer's-related changes in the brain than men, according to new research presented at the European Academy of Neurology (EAN) Congress 2026.

28 Jun 2026

Glucosamine may worsen Alzheimer’s by fueling abnormal brain glycosylation

A Nature Metabolism study identifies brain hyperglycosylation as a metabolic driver of Alzheimer’s disease, with increased N-glycan biosynthesis seen in human AD tissue and mouse models. Reducing glycosylation improved memory in AD mice, while glucosamine worsened memory deficits in 5xFAD mice and was associated with poorer outcomes in dementia patients.

14 Jun 2026

Blood biomarkers may detect Alzheimer’s risk before symptoms appear

For the first time, researchers found blood biomarkers for Alzheimer's disease that correlated with minor cognitive differences in midlife adults who did not have dementia.

28 May 2026

Poor sleep may flag early Alzheimer’s risk in genetically vulnerable older women

Poorer subjective sleep quality was linked to worse visual memory and greater limbic tau burden in older women with higher genetic risk for Alzheimer’s disease. The findings suggest sleep complaints may help identify women at elevated risk for early AD-related brain and cognitive changes, but larger longitudinal studies are needed.

20 May 2026

How the immune system may influence Alzheimer’s, Parkinson’s, and related diseases

This review argues that neurodegeneration is shaped not only by toxic protein buildup but also by immune signaling, with microglia and T cells able to either protect the brain or worsen damage depending on context. It also highlights aging, head injury, and viral infection as major forces that reshape CNS immunity and may influence disease progression and future treatment strategies.

16 Apr 2026

KAIST proposes novel strategy for multifactorial Alzheimer's treatment

Conventional treatments of Alzheimer's disease, one of the most common forms of dementia, have been largely focused on targeting individual pathological features.

27 Jan 2026

Study elucidates how anti-amyloid antibody therapy lecanemab works in Alzheimer's disease

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline.

25 Nov 2025

Oral arginine reduces amyloid buildup in Alzheimer’s models

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is one of the leading causes of dementia worldwide, and currently has no definitive cure. Although antibody-based therapies that target amyloid β (Aβ) have recently been developed, their clinical effectiveness remains limited.

21 Nov 2025

Newly identified microglia subtype offers protection against Alzheimer’s disease

In Alzheimer's disease, the leading cause of dementia, microglia-the brain's immune defenders-can act as both protectors and aggressors, shaping how the disease progresses.

5 Nov 2025

Disruption of glial circadian rhythms linked to Alzheimer's disease progression

Alzheimer's disease is notorious for scrambling patients' daily rhythms. Restless nights with little sleep and increased napping during the day are early indicators of disease onset, while sundowning, or confusion later in the day, is typical for later stages of the disease.

23 Oct 2025

Obesity-linked fat vesicles accelerate amyloid aggregation in Alzheimer’s disease

Researchers discuss the role of extracellular vesicles as a potential link between obesity and Alzheimer’s disease.

9 Oct 2025

Cell messengers signal amyloid plaque buildup in obese individuals

Obesity has long been acknowledged as a risk factor for a wide range of diseases, but a more precise link between obesity and Alzheimer's disease has remained a mystery – until now.

3 Oct 2025

Study links high neuroinflammation in young people with Down Syndrome to Alzheimer's risk

Down syndrome is associated with accelerated aging. It is estimated that up to 90% of individuals with the condition develop Alzheimer's disease before the age of 70. A study by researchers at the University of São Paulo (USP) in Brazil identified high levels of neuroinflammation in young individuals with Down syndrome, an additional factor explaining the high prevalence of Alzheimer's disease in older people with the condition. The discovery paves the way for strategies to prevent and monitor the disease.

3 Oct 2025

Can roselle help fight inflammation? New review suggests strong potential

A new review highlights the anti-inflammatory potential of Hibiscus sabdariffa (roselle), synthesizing evidence from 25 studies published between 2019 and 2024. Most findings are from preclinical models, but they point to promising roles in cardiovascular, metabolic, neuroprotective, and anticancer health.

28 Sep 2025

How food choices and cooking methods drive brain inflammation and disease

Researchers reviewing evidence in NeuroSci show how dietary AGEs and their interaction with RAGE drive oxidative stress, inflammation, and neurodegeneration. They highlight how cooking methods and diet choices could lower AGE burden and protect brain health, while calling for rigorous clinical trials.

24 Sep 2025